Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis

Respiratory Research

Table 3 Cox analysis for risk factors for an acute exacerbation of idiopathic pulmonary fibrosis

	HR	(95 % CI)	P Value
Treatment after the diagnosis
Immunosuppressive agent
Unadjusted	3.35	(1.27 to 8.84)	0.014
Cardiovascular diseases
Unadjusted	2.49	(1.00 to 6.19)	0.049
Adjusted^a	3.21	(1.24 to 8.32)	0.016
GAP stage (≥II)
Unadjusted	3.88	(1.54 to 9.80)	0.004
Adjusted^a	3.23	(1.22 to 8.51)	0.018
Serum markers
LDH, U/L, Cut off point = 180
Unadjusted	4.00	(0.92 to 17.46)	0.065
Adjusted^a	3.49	(0.78 to 15.57)	0.101
KL-6, U/mL, Cut off point = 946
Unadjusted	1.57	(0.67 to 3.68)	0.296
Adjusted^a	1.53	(0.65 to 3.59)	0.326
SP-D, ng/mL, Cut off point = 194.7
Unadjusted	3.17	(1.21 to 8.31)	0.019
Adjusted^a	2.69	(0.98 to 7.42)	0.056
BAL fluid findings
Lymphocytes, %, Cut off point = 10.15
Unadjusted	2.01	(0.89 to 4.52)	0.091
Adjusted^a	2.03	(0.90 to 4.57)	0.087
Neutrophils, %, Cut off point = 1.77
Unadjusted	4.04	(0.92 to 17.79)	0.065
Adjusted^a	3.54	(0.79 to 15.94)	0.100
Eosinophils, %, Cut off point = 3.21
Unadjusted	3.27	(1.29 to 8.29)	0.013
Adjusted^a	2.89	(1.11 to 7.51)	0.029

Abbreviations: HR hazard ratio, CI confidence interval, GAP gender-age-physiology, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D, BAL bronchoalveolar lavage
^aAdjusted for immunosuppressive agent therapy

ISSN: 1465-993X